

	Total (n=87)	RDI <85% (n=40)	RDI ≥85% (n=47)	<i>P</i> value^a	HER2+ (n=66)	HER2- (n=21)	<i>P</i> value^a
Median follow-up, months (95% CI)	6.7 (5.4–8.0)	5.7 (4.3–8.6)	7.2 (5.1–9.9)	0.345	7.2 (5.6–9.9)	5.2 (0.9–8.0)	0.035
PFS				0.623			<0.001
No. of events/patients	49/87	17/40	32/47		35/66	14/21	
Median PFS, months (95% CI)	8.1 (5.4–10.1)	8.7 (4.8–NE)	8.1 (4.8–10.1)		8.8 (6.7–14.8)	2.5 (1.4–8.7)	
6-month PFS, % (95% CI)	60.0 (47.8–70.2)	56.4 (36.0–72.5)	61.7 (45.7–74.2)		66.4 (52.3–77.2)	39.2 (17.7–60.3)	
12-month PFS, % (95% CI)	29.9 (18.0–42.7)	28.6 (10.1–50.6)	30.4 (16.0–46.1)		35.8 (21.3–50.6)	10.5 (0.7–35.4)	

CI: confidence interval; HER2: human epidermal growth receptor 2; NE: not estimable; PFS: progression-free survival; RDI: relative dose intensity

^a Based on log-rank test.